Posted by Michael Wonder on 07 Jun 2017
Pfizer receives FDA fast track designation for tafimidis for transthyretin cardiomyopathy
6 June 2017 - Tafamidis, an investigational medicine for TTR-CM a rare, progressive and fatal disease, is currently in phase 3 development.
Pfizer announced today that the U.S. FDA granted fast track designation to tafamidis, the company’s investigational treatment for transthyretin cardiomyopathy (TTR-CM). This rare disease is associated with progressive heart failure and is universally fatal.
Currently in Phase 3 clinical development for TTR-CM, tafamidis is being evaluated for its potential to reduce mortality and cardiovascular-related hospitalisations.
